Posted by Michael Wonder on 22 Sep 2020
Gyroscope Therapeutics granted FDA fast track designation for GT005, an investigational gene therapy for dry age-related macular degeneration
22 September 2020 - Gyroscope Therapeutics today announced that the U.S. FDA has granted fast track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
GT005 is an investigational one-time AAV based gene therapy that is delivered under the retina and is intended to slow the progression of geographic atrophy that can lead to blindness.
